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Pulmonary vascular disease (PVD) is a devastating condition
affecting cardiac function and precipitating heart failure, and
is associated with high morbidity and mortality rates. The
progressive increase in pulmonary artery pressure (pulmo-
nary arterial hypertension (PAH)) is the main haemodynamic
manifestation of a complex of pathological changes in the
vascular tree leading to right ventricular failure.
Whereas the pathogenesis of PAH is multifactorial, the
ﬁnal effect is vasoconstriction within the pulmonary circula-
tion, which leads to an increase in pulmonary vascular resis-
tance and pulmonary artery pressure. Indeed, changes in the
main signalling pathways, i.e. the endothelin, nitric oxide and
prostacyclin pathways, either alone or in combination, may
contribute to an increase in pulmonary vascular tone, and to
morphological changes (‘remodelling’) of the vascular wall
that are difﬁcult to reverse in those patients with a long his-
tory of PAH.
Inﬂammation holds a key position in the pathophysiology
of pulmonary hypertension; however, there is still a consid-
erable amount to be learned regarding potential stimuli and
triggers of inﬂammation, including infectious agents. In the
present issue, Pullamsetti et al. will give a better insight into
the inducers/triggers of chronic inﬂammation and infection,
and on the inﬂammatory mediators and cells that are
involved in pulmonary hypertension.
The precise role of infectious diseases in the pathophysiol-
ogy of PAH is under investigation, but PVD has been associ-
ated with various infectious diseases, such as human
immunodeﬁciency virus (HIV) disease and schistosomiasis,
and with other clinical conditions that are commonly associ-
ated with infectious agents, including chronic liver disease
with portal hypertension, chronic obstructive pulmonary dis-
eases, cystic ﬁbrosis, and pulmonary interstitial diseases.
PVD associated with HIV infection represents a challenge
for physicians dealing with HIV-infected patients. The intro-
duction of potent antiretroviral treatment for HIV-infected
individuals resulted in longer and better survival and lower
mortality from opportunistic infections among this large pop-
ulation of patients that, according to UNAIDS, in 2008
accounted for 33.4 million people. However, the longer sur-
vival of HIV-infected patients has also drawn attention to
some severe complications such as neoplasm, neurological
diseases, and cardiovascular involvement. Most of the cur-
rently increased attention regarding cardiovascular involve-
ment in the course of HIV infection has focused on the
metabolic disorders caused by antiretrovirals and the subse-
quent risk of cardiovascular diseases. However, since the
beginning of the AIDS epidemic, a severe cardiovascular–pul-
monary disease has been observed, i.e. PAH that is clinically
and histologically indistinguishable from the other forms of
PAH. In their review, Cicalini et al. report the main epidemi-
ological, clinical and therapeutic highlights and the new
hypotheses on the pathogenesis of HIV-related PAH.
HIV infection is widespread in the world’s population, but
also other infections related to pulmonary hypertension,
such as schistosomiasis, are also a concern, owing to their
diffusion worldwide. Schistosomiasis (bilharzia) is the third
leading endemic parasitic disease in the world, following
malaria and amoebiasis. More than 200 million individuals are
infected, and another 600 million are at risk of acquiring the
infection. The disease is endemic in eastern South America,
the Caribbean islands, East Asia and different areas of China
and the Middle East; sub-Saharan Africa is the area with the
highest endemicity. It is calculated that 2–5 million people
worldwide develop PAH because of schistosomiasis. How-
ever, only few countries have managed to eradicate the
infection or have undertaken successful and sustainable con-
trol programmes. Schistosoma worms live in the perivisceral
veins of the intestine, liver and genitourinary systems, and
have a life cycle that involves certain species of freshwater
snails. The lung is a mandatory step in the parasite’s life
cycle. This causes both acute and chronic pulmonary lesions,
depending on the cycle phase, as discussed in the review by
Butrous et al.
Other infections have been more recently associated with
PAH, and include pertussis, tuberculosis, human herpesvi-
rus 8 infection, and ﬁlariasis and other helminthic diseases.
Pertussis is ranked among the ten leading causes of child-
hood mortality, and causes an estimated 254 000 paediatric
deaths every year. The most catastrophic clinical complica-
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tion of pertussis in infants is intractable pulmonary hyperten-
sion, leading to failure and shock, and currently recognized
as a frequent problem in infants with fatal pertussis. In fact,
pertussis should be suspected in any infant death associated
with marked leukocytosis, bronchopneumonia, or refractory
pulmonary hypertension, particularly in children aged
<4 months.
Interestingly, the role of bacteria in the development of
pulmonary hypertension could also be associated with their
capacity to enhance ﬁbrotic remodelling, as hypothesized fol-
lowing thrombosis in patients with chronic thromboembolic
pulmonary hypertension, thus resulting in a misguided throm-
bus resolution. In these patients, thrombus infection appears
to be a trigger in the evolution of chronic thromboembolic
pulmonary hypertension.
There is a noticeable lack of awareness regarding the
association of pulmonary hypertension with infectious
diseases; the reviews in this issue will increase its under-
standing among specialists involved in the care of patients
with infections.
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